Pure Global
NCT01713972

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors
Manisha Shah·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
dabrafenib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Manisha Shah
Funder
Ohio State University Comprehensive Cancer Center
Location
Columbus,Houston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Nov 19, 2012
End date
Dec 26, 2018
Enrollment
23 participants
Primary outcome

Incidence of adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4,Maximum tolerated dose, defined as the dose below the dose where at least 2 dose limiting toxicities (DLTs) are observed, graded using CTCAE v4

Summary

This phase I trial studies the side effects and best dose of dabrafenib and pazopanib
 hydrochloride when given together in treating patients with advanced malignant tumors.
 Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of
 the enzymes needed for cell growth

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01713972
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01713972 through Pure Global AI's free database. This Phase 1 trial is sponsored by Manisha Shah and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 23 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.